Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1.

Dolinsky VW, Chan AY, Robillard Frayne I, Light PE, Des Rosiers C, Dyck JR.

Circulation. 2009 Mar 31;119(12):1643-52. doi: 10.1161/CIRCULATIONAHA.108.787440. Epub 2009 Mar 16.

PMID:
19289642
2.

The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling.

Calamaras TD, Lee C, Lan F, Ido Y, Siwik DA, Colucci WS.

Free Radic Biol Med. 2015 May;82:137-46. doi: 10.1016/j.freeradbiomed.2015.01.007. Epub 2015 Jan 21.

3.

Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction.

Ikeda Y, Sato K, Pimentel DR, Sam F, Shaw RJ, Dyck JR, Walsh K.

J Biol Chem. 2009 Dec 18;284(51):35839-49. doi: 10.1074/jbc.M109.057273.

4.

Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice.

Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR.

Biochim Biophys Acta. 2013 Oct;1832(10):1723-33. doi: 10.1016/j.bbadis.2013.05.018. Epub 2013 May 22.

5.

Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.

Zhu J, Ning RB, Lin XY, Chai DJ, Xu CS, Xie H, Zeng JZ, Lin JX.

Am J Hypertens. 2014 Aug;27(8):1112-24. doi: 10.1093/ajh/hpu017. Epub 2014 Mar 6.

PMID:
24603314
6.

Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt.

Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, Dyck JR.

J Biol Chem. 2008 Aug 29;283(35):24194-201. doi: 10.1074/jbc.M802869200. Epub 2008 Jun 18.

7.

Resveratrol prevents pathological but not physiological cardiac hypertrophy.

Dolinsky VW, Soltys CL, Rogan KJ, Chan AY, Nagendran J, Wang S, Dyck JR.

J Mol Med (Berl). 2015 Apr;93(4):413-25. doi: 10.1007/s00109-014-1220-8. Epub 2014 Nov 15.

PMID:
25394677
8.

Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways.

Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC.

Free Radic Biol Med. 2005 Jan 15;38(2):243-57.

PMID:
15607907
9.
10.

Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte.

Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR.

J Biol Chem. 2004 Jul 30;279(31):32771-9. Epub 2004 May 24.

11.

Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt.

Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K, Yamada T, Nishizawa T, Noda A, Cheng XW, Murate T, Koike Y, Murohara T, Yokota M, Nagata K.

J Hypertens. 2008 Aug;26(8):1669-76. doi: 10.1097/HJH.0b013e328302f0f7.

PMID:
18622247
12.

Expression of an active LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy.

Noga AA, Soltys CL, Barr AJ, Kovacic S, Lopaschuk GD, Dyck JR.

Am J Physiol Heart Circ Physiol. 2007 Mar;292(3):H1460-9. Epub 2006 Nov 10.

13.

Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway.

Thandapilly SJ, Louis XL, Yang T, Stringer DM, Yu L, Zhang S, Wigle J, Kardami E, Zahradka P, Taylor C, Anderson HD, Netticadan T.

Eur J Pharmacol. 2011 Oct 1;668(1-2):217-24. doi: 10.1016/j.ejphar.2011.06.042. Epub 2011 Jul 6.

PMID:
21756902
14.

A novel complex I inhibitor protects against hypertension-induced left ventricular hypertrophy.

Matsumura N, Robertson IM, Hamza SM, Soltys CM, Sung MM, Masson G, Beker DL, Dyck JR.

Am J Physiol Heart Circ Physiol. 2017 Mar 1;312(3):H561-H570. doi: 10.1152/ajpheart.00604.2016. Epub 2017 Jan 6.

15.

SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

Tang X, Chen XF, Wang NY, Wang XM, Liang ST, Zheng W, Lu YB, Zhao X, Hao DL, Zhang ZQ, Zou MH, Liu DP, Chen HZ.

Circulation. 2017 Nov 21;136(21):2051-2067. doi: 10.1161/CIRCULATIONAHA.117.028728. Epub 2017 Sep 25.

16.

MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.

Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S, Izuhara M, Nakao T, Nishino T, Otsu K, Kita T, Kimura T, Ono K.

Circ Res. 2015 Jan 16;116(2):279-88. doi: 10.1161/CIRCRESAHA.116.304707. Epub 2014 Oct 31.

PMID:
25362209
17.

Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1/AMPK pathway.

Zhang Z, Wang S, Zhou S, Yan X, Wang Y, Chen J, Mellen N, Kong M, Gu J, Tan Y, Zheng Y, Cai L.

J Mol Cell Cardiol. 2014 Dec;77:42-52. doi: 10.1016/j.yjmcc.2014.09.022. Epub 2014 Sep 28.

PMID:
25268649
18.

AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice.

Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, Xu W, Wiczer B, Bernlohr DA, Bache RJ, Chen Y.

Hypertension. 2008 Nov;52(5):918-24. doi: 10.1161/HYPERTENSIONAHA.108.114702. Epub 2008 Oct 6.

20.

A novel, de novo mutation in the PRKAG2 gene: infantile-onset phenotype and the signaling pathway involved.

Xu Y, Gray A, Hardie DG, Uzun A, Shaw S, Padbury J, Phornphutkul C, Tseng YT.

Am J Physiol Heart Circ Physiol. 2017 Aug 1;313(2):H283-H292. doi: 10.1152/ajpheart.00813.2016. Epub 2017 May 26.

Supplemental Content

Support Center